PCVX - NASDAQ
Vaxcyte, Inc.
$47.70
+1.1%Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
At a Glance
Live SnapshotNo Revenue Data
PCVX has not reported any revenue values in the available annual periods.
Vaxcyte, Inc. Profit Bridge
Profitability Analysis
Vaxcyte, Inc. Income Statement
PCVX • NASDAQ
| Vaxcyte, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
GROSS PROFIT | |||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1.4M) | (1.2M) | (1M) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.4M | -1.2M | -1M | 0.0 | |
OPERATING INCOME | |||||||||
(923.7M) | (569.5M) | (468M) | (232.3M) | (103.7M) | (88.2M) | (52.9M) | (35.5M) | (17.4M) | |
(129.4M) | (92.9M) | (60.7M) | (39.8M) | (25.3M) | (14.6M) | (7.3M) | (5.4M) | (5M) | |
(794.3M) | (476.6M) | (332.3M) | (169.5M) | (78.4M) | (73.6M) | (45.6M) | (30.1M) | (12.8M) | |
-923.7M | -569.5M | -468M | -232.3M | -103.7M | -89.6M | -54.2M | -35.5M | -17.8M | |
PRE-TAX INCOME | |||||||||
(0.0) | (0.0) | (0.0) | (2K) | (7K) | (7K) | (40K) | (75K) | (0.0) | |
119.7M | 110M | 62.9M | 8.4M | 337K | 237K | 592K | 828K | 0.0 | |
(0.0) | (0.0) | (75M) | (23M) | (0.0) | (0.0) | (0.0) | (5.2M) | (0.0) | |
157M | 105.6M | 65.8M | 8.8M | 3.6M | 364K | 3.9M | 6M | 595K | |
-766.6M | -463.9M | -402.3M | -223.5M | -100.1M | -89.2M | -50.3M | -29.5M | -17.2M | |
NET INCOME | |||||||||
-766.6M | -463.9M | -402.3M | -223.5M | -100.1M | -89.2M | -50.3M | -29.5M | -17.2M |
SEC Filings
PCVX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 02, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 19, 2025 | December 18, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your PCVX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.